# Efficacy of Omalizumab as Add on Therapy for Minority Patients With Moderate to Severe Asthma

> **NCT00180011** · PHASE2,PHASE3 · COMPLETED · sponsor: **DiMango, Emily, M.D.** · enrollment: 18 (actual)

## Conditions studied

- Asthma

## Interventions

- **DRUG:** Omalizumab

## Key facts

- **NCT ID:** NCT00180011
- **Lead sponsor:** DiMango, Emily, M.D.
- **Sponsor class:** INDIV
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-09
- **Primary completion:** 2012-02
- **Final completion:** 2012-02
- **Target enrollment:** 18 (ACTUAL)
- **Last updated:** 2012-02-28

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00180011

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00180011, "Efficacy of Omalizumab as Add on Therapy for Minority Patients With Moderate to Severe Asthma". Retrieved via AI Analytics 2026-09-21 from https://api.ai-analytics.org/clinical/NCT00180011. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*